Comerica Bank Sells 48,571 Shares of Pfizer Inc. $PFE

Key Points

• Comerica Bank reduced its Pfizer stake by 2.6%, selling 48,571 shares in Q3 and ending the quarter with 1,831,382 shares worth about $46.66 million.
• Positive pipeline and regulatory news: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying (potential international revenue upside from 2026+), Pfizer reported promising Phase‑2 results for tilrekimig, and it advanced an early‑stage oncology candidate, reinforcing R&D momentum.
• Investor and analyst backdrop: institutional investors own roughly 68% of the stock (Fairfax added 240,000 shares to 890,900), analysts’ consensus is a “Hold” with an average target of $28.05, and Pfizer recently beat Q4 EPS estimates while revenue was down 1.2% year‑over‑year.

Comerica Bank lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,831,382 shares of the biopharmaceutical company's stock after selling 48,571 shares during the quarter. Comerica Bank's holdings in Pfizer were worth $46,664,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of PFE. Texas Capital Bancshares Inc TX bought a new stake in shares of Pfizer during the third quarter valued at approximately $64,000. Tepp RIA LLC bought a new position in Pfizer in the 3rd quarter valued at approximately $236,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Pfizer during the 3rd quarter valued at $323,000. Wealth Advisors of Tampa Bay LLC boosted its stake in Pfizer by 4.7% during the 3rd quarter. Wealth Advisors of Tampa Bay LLC now owns 147,400 shares of the biopharmaceutical company's stock valued at $3,756,000 after purchasing an additional 6,630 shares during the last quarter. Finally, Fairfax Financial Holdings Ltd. Can increased its holdings in shares of Pfizer by 36.9% in the 3rd quarter. Fairfax Financial Holdings Ltd. Can now owns 890,900 shares of the biopharmaceutical company's stock worth $22,691,000 after purchasing an additional 240,000 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla somatrogon: Pfizer Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Argus raised Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 24th. TD Cowen reissued a "hold" rating on shares of Pfizer in a research report on Tuesday, December 30th. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a "neutral" rating and a $26.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.05.

Pfizer Stock Performance

PFE stock opened at $26.60 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a market cap of $151.23 billion, a P/E ratio of 19.56 and a beta of 0.47. The stock's fifty day moving average price is $26.50 and its 200-day moving average price is $25.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer's revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.